STUDIES OF CALCIUM METABOLISM IN MULTIPLE MYELOMA WITH CALCIUM⁴⁷ AND METABOLIC-BALANCE TECHNIQUES

BY MICHAEL Z. LAZOR,* LEON ROSENBERG,† AND PAUL CARBONE

(From the Radiation Branch, Metabolism Service and Medicine Branch, National Cancer Institute, Bethesda, Md.)

(Submitted for publication November 29, 1962; accepted April 11, 1963)

Despite the fact that approximately 90% of patients with multiple myeloma present themselves with skeletal complaints (1, 2), few studies of bone mineral metabolism in this disease have been reported. Stable calcium studies in multiple myeloma were first reported in the literature by Blatherwick (3) in 1916. Since that time there have been only infrequent reports using balance techniques, or isotopic-tracer methods, or both. Adams, Mason, and Bassett (4) used metabolicbalance techniques to investigate the influence of ACTH on mineral metabolism in three patients with multiple myeloma. Case studies of one or two patients using tracer methods and balance techniques have been reported by Anderson, Emery, McAllister, and Osborn (5), after a therapeutic dose of Ca45; by Spencer, Li, Samachson, and Laszlo (6), who have studied the comparative excretion and retention of Sr⁸⁵ and Ca⁴⁵; and recently, by Skoog, Adams, and MacDonald (7), who have reported balance and Sr⁸⁵-tracer studies in a patient with multiple myeloma treated with various combination of hormones.

The study of calcium metabolism in multiple myeloma is of great interest, since diffuse osteoporosis, or osteolytic lesions, or both, are most always present, and hypercalcemia is a frequent (8) but poorly understood complication. With the increasing availability of clinically suitable radioactive isotopes of calcium, calcium-balance measurements can now be supplemented with kinetic-tracer studies. Stable calcium-balance studies alone measure only the net difference between bone formation and resorption. With Ca⁴⁷tracer studies in addition to balance techniques, calcium absorption, endogenous fecal calcium, exchangeable or miscible calcium, and miscible calcium turnover rates can be estimated. The present report describes studies of calcium metabolism using Ca^{47} and balance techniques in six patients with multiple myeloma. These studies indicate that the gut is an important source of calcium loss in multiple myeloma, and that the endogenous fecal calcium contributes significantly to the negative calcium balance uniformly found in our patients.

MATERIALS AND METHODS

Patients. Three men and three women with multiple myeloma were studied. Their ages ranged from 44 to 65 years. All patients were ambulatory during the entire study. The diagnosis of multiple myeloma was established by abnormalities in serum-protein pattern, bonemarrow examination, and skeletal X rays consistent with that disease. Serum calcium, phosphorus, and alkaline phosphatase were within normal limits in each patient (Table I). The term "untreated," as used in this patient population, refers to the absence of systemic treatment during the 3 months before study.

Metabolic balance. All patients were studied in a metabolic-balance ward while they were maintained on fixed metabolic-balance diets, analyzed in triplicate. Four patients received approximately 200 mg Ca and 800 mg P daily, and two received approximately 500 mg Ca and 1,000 mg P daily. All patients were maintained on the specified diets for 8 to 10 days before the balance studies to allow for equilibration to the low-calcium diet and to the metabolic routine. Refused food and emeses were saved, analyzed, and substracted from the daily intake for that period. Fluid intake was kept constant by providing a fixed quantity of distilled water daily. Voided urine specimens were immediately pooled in a refrigerated jar containing 10 ml of concentrated HCl. Stools were separated at intervals of 4 days with carmine markers. The following analytical methods were used: nitrogen, macro-Kjeldahl (9); urinary, fecal, and dietary phosphorus, Taussky and Shorr (10); serum phosphorus, Reiner (11); urinary, fecal, and dietary calcium, Kochakian and Fox (12); and serum calcuim, MacIntyre (13). Daily urine samples were anlyzed for nitrogen. Sample of 4-day pooled stools were analyzed for calcium, phosphorus, and nitrogen.

Intravenous Ca^{47} studies. All patients were given 30 $\mu c Ca^{47}Cl_2$ intravenously before breakfast in 10 ml of iso-

^{*} Present address: Hartford Hospital, Hartford, Conn. † Present address: Grace-New Haven Hospital, New Haven, Conn.

TABLE 1Clinical and laboratory data in six patients with multiple myclonasubjectWiApeSerum proteins anydonaAltalite patesRum blocusBoot marcovBoot marcovBoot statesLE6364F159.73.36.49.39.4100 mlMary totakStateBootStateLE6364F159.73.36.49.39.4100 mlMary totakStateStateUT6364F159.73.36.49.34.318Mary totakStateUT6364F159.73.36.49.34.3190 mlStateUS64M211.13.27.979.419Mary totakMary totakMary totakNS<[71]6544M2213.02.5/10.389.83.51.5Plaama cellaOronatellon 177 ml totakNS<[71]6544M2213.02.5/10.389.83.51.5Plaama cellaOronatellon 177 ml totakNS<[71]6544M2213.02.5/10.3987.32.5Mary totakMary totakMary totakNS<[72]6544191919191919Mary totakMary totakMary totak <td< th=""><th></th><th></th><th colspan="2">Therapy</th><th></th><th colspan="3">tiane protocol 10 months be fore study X ray to thoracic spine 1 month before admission. None</th><th>5-Filuorouracil during present admission</th><th>X ray to spine 1 month before ill, study</th><th>None</th><th>Urethane and X ray to spine 21 months before study; Vinca- leucoblastine 3 months before study.</th></td<>			Therapy			tiane protocol 10 months be fore study X ray to thoracic spine 1 month before admission. None			5-Filuorouracil during present admission	X ray to spine 1 month before ill, study	None	Urethane and X ray to spine 21 months before study; Vinca- leucoblastine 3 months before study.			
TABLE 1 Table in the protein of the protein the protein of the protein the protein of t		loma		Skeletal X rays		Single lytic lesion, left frontal hone: diffuse	osteoporosis	Compression T7 and 9 diffuse osteoporosis	Very extensive osteo- lytic lesions; com- pression T7, 8, 11,	and L1; diffuse oste porosis	Unchanged from the first study	Extensive osteolytic lesions involving skı humerus, and ribs;	compression fractur T7; diffuse osteo- porosis	Diffuse osteoporosis	Minimal osteolytic in- volvement of ribs and pelvis; diffuse osteoporosis
TABLE I Alter in Six Patients un Polos in Toolal A/Gr Phose Scun Phose Scun Phose Weight no Multistate Phose Scun Phose Scun Phose Weight no Multistate Phose Scun Phose Scun Phose Normal Maternal Phose Scun Phose Scun Phose Normal Maternal Phose Scun Phose Normal Maternal Phose Scun Phose Scun Phose Normal Norma Normal Normal No		vith multiple mye		Bone marrow		Many plasma cells		Replaced by plasma cells	Plasma cells, 25%		Plasma cells, 5 to 30%	"Almost all cells are plasma cells"		Plasma cells, 40%	Plasma cells, 98%
TABLE TABLE Clinical and laboratory data in six $j_{\rm rest}$ Subject Wt Age Sex Durational and laboratory data in six $j_{\rm rest}$ TABLE ke wars Durational and laboratory data in six $j_{\rm rest}$ Durational and laboratory data in six $j_{\rm rest}$ TABLE ke wars months Errum proteinal Alphane Alfanic Conditional ke wars months $g_1/00$ ml King- Alfanic Months LE 65 64 F 15 9.7 3.3/ 64 8 cm 9.3 4.3 OT 69 61 M 22 11.1 3.2/ 7.9 7 9.2 4.0 NS [1] 65 44 M 22 13.0 2.5/10.5 9 8 9.3 3.5 NS [2] 65 44 M 23 13.0 2.5/10.5 9 8 10.2 3.5 NS [2] 65 66 M 1 9.2 2.9	I	ory data in six patients u	Blood	urea nitrogen	mg/ 100 ml	18		19	15		15	22		17	14
Clinical and laboratory dataSubjectWiAgeSexDuration of a clinical and laboratory datakeyearsLESex $\frac{Duration of a clinical and laboratory datakeyearsmonths\frac{Contal A / G^*}{T 0 tal A / G^*}Altatine clinical and laboratory dataLE6564F159.7\frac{String a f a / G^*}{A / m + G^*}\frac{Methe clinical a / G^*}{A / m + G^*}LE6564F159.7\frac{3.2 / 7.9}{A / m + G^*}79.2NS [1]6544M2213.02.5 / 10.589.3NS [2]6544M2313.02.5 / 10.598NS [2]65M19.22.9 / 6.3810.2NS [2]65M19.22.9 / 6.3810.2NS [2]65F513.02.5 / 10.598NS [2]65M19.22.9 / 6.3810.2NS [2]65F511.82.2 / 9.659.2HK6253F249.03.6 / 5.4810.2$	TABLE		Serum	phorus	mg/ 100 ml	4.3		4.0	3.5		2.5	3.9		3.5	4.5
Image: Climical and laborateSubjectWtAgeSexDura- mondsSerum proteins ploseAltalineSubjectWtAgeSexmyelonialSingle of AreaAltalineLE6564F159.73.3/6.48UT6564K159.73.3/6.48UT6564M211.13.2/7.97NS [1]6544M2213.02.5/10.59NS [2]65M19.22.5/10.59NS [2]65M19.22.5/10.59NS [2]65M19.22.5/10.59NS [2]65F213.02.5/10.59NS [2]65M19.22.9/6.38NS [2]65F23.6/5.48NS [2]65F29.03.6/5.48HK6253F249.03.6/5.48				Call	mg/ 100 ml	9.5		9.2	9.8		8.7	10.2		9.2	10.0
Clinical anSubjectWtAgeSexDura- NelonáSerum proteina A/G*LE6564F159.73.3/ 6.4UT6564F159.73.3/ 6.4UT6961M211.13.2/ 7.9UT6961M211.13.2/ 7.9NS [1]6544M2211.13.2/ 7.9NS [2]6544M2213.02.5/10.5NS [2]6544M2513.02.5/10.5NS [2]6565M19.22.5/10.5NS [2]6574M2513.02.5/10.5NS [2]6574M2513.02.5/10.5NS [2]6574703.66.57.9NS [2]6574703.67.9NS [2]6574703.67.9NS [2]6574703.67.9NS [2]6574703.67.9HK62537249.03.6/ 5.4		d laborato	Alkaline	phatase	King- Arm-	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	1	1	c 0		a	ø		ŝ	œ
SubjectWtAgeSexDura- weursSerumSubjectWtAgeSexUura- moutisSerumLE6564F159.7UT6564F159.7OT6564M211.1NS [1]6544M2213.0NS [2]6544M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574M2313.0NS [2]6574765311.8HK6353F249.0		Clinical an	proteins	A/G*	g/100 ml	3.3/ 6.4		5. 7 / 7. 8	2.5/10.5		2.5/10.5	2.9/ 6.3		2.2/ 9.6	3.6/ 5.4
SubjectWtAgeSexDura- motionaLE6564F15LE6564F15OT6564M2NS [1]6544M22NS [2]6544M25NS [2]6544M25NS [2]6565M1NS [2]6565M2NS [2]6565F5NS [2]6565F5HK6353F24			Serum	Total		9.7	•	1.11	13.0		13.0	9.2		11.8	0.0
SubjectWtAgeSexLEisyearsisisLE6564FOT6564MNS [1]6544MNS [2]6544MNS [2]6544MNS [2]6565FHK656553FHK625353F			Dura- tion of	myeloma	months	15	ç	N :	22	!	25	1	. 1	ю	24
Subject Wt Age LE 65 64 LE 65 64 NS<[1]				Sex		۲.	ž		W	;	¥ 2	M	ſ	<u>تر</u>	۴4
Subject Wt LE 65 LE 65 OT 69 NS [1] 65 RF 76 RF 76 AS 65 HK 62				Age	years	64	ţy	5 3	4 4	:	#	8	;	8	ß
Subject LE NS [1] NS [1] NS [2] AS HK				Wt	84	65	0ý		8	ţ	8 7	ę	ţ	8	62
				Subject		LE	oT			Log an	[7] CV	2	S V	SA	HK

•

CALCIUM" AND METABOLIC BALANCE STUDIES IN MULTIPLE MYELOMA

1239

* Albumin/globulin ratio.

•

tonic saline, except patient LE, who received 15 μ c. Ca⁴⁷ has a half-life of 4.7 days and emits a high-energy gamma ray of 1.3 Mev as well as a beta particle in its decay to scandium⁴⁷ (14). The Ca⁴⁷ specific activity on receipt from Union Carbide Corporation in Oak Ridge, Tennessee, was approximately 200 mc per g. All counting was done in a single-channel gamma-ray spectrometer, with the lower gate set at 400 Kev to exclude Sc47. Two-ml serum samples were counted in an automatic well-type scintillation counter. Five-hundred-ml samples of daily urine and 500-ml samples of homogenized, 4-day pooled stools were counted in 1-quart paint cans over a 2-inch NaI crystal of a well-type gamma counter. Samples of the original Ca⁴⁷ solution were also counted, and the results of the biological samples were expressed as fractions or percentages of administered dose. All samples were counted sufficiently long to insure statistical counting errors of less than 5%.

Oral Ca⁴¹ studies and calcium absorption. Three patients, AS, HK, and NS, were given Ca⁴¹ orally as well as intravenously. The oral isotope was administered 7 to 10 days before the intravenous Ca47 in all cases. One μc of Ca⁴⁷ was given orally in distilled water while the patient was eating breakfast. All stools were counted until activity returned to background, an interval varying from 5 to 10 days. The fractions of dietary calcium and Ca⁴⁷ absorbed are assumed to be identical, assuming that Ca⁴⁷ and stable calcium are completely mixed before absorption, and that neither isotope is absorbed preferentially. Absorbed dietary calcium (milligrams per day) was calculated from Equation 1 by determining the fraction of oral Ca47 not absorbed: calcium absorption $= (1 - fs') \times dietary$ calcium, where fs' =fraction of orally administered Ca47 that is not absorbed. Calcium absorption was also calculated from the intravenous Ca⁴⁷ data by the following relationships: a) total fecal calcium = unabsorbed dietary calcium + endogenous fecal calcium and b) dietary calcium = unabsorbed dietary calcium + absorbed dietary calcium. The total fecal calcium and the dietary calcium were determined by the



FIG. 1. SERUM SPECIFIC ACTIVITY IN PATIENT OT AFTER THE IV INJECTION OF CA⁴⁷. The final exponential is extrapolated to the ordinate at zero time to determine E. The t_1 (4.2 days) is the interval during which the serum specific activity falls to one-half of its value at zero time. K then = $\ln 2/t_1$.

.

analytical methods of Kochakian and Fox (12). The endogenous fecal calcium was determined by Equation 2 described below. Relationship a) can then be solved for unabsorbed dietary calcium, which is substituted in relationship b) to determine the absorbed dietary calcium.

Endogenous fecal calcium. Endogenous fecal calcium is defined as the calcium secreted into the gut (total digestive-juice calcium) minus the absorbed secreted calcium. The following relationship, Equation 2, was used to estimate the endogenous fecal calcium (milligrams per day): endogenous fecal calcium = $(U_{oa}/\Delta t) \times fs/fu$, where Δt = entire period Ca⁴⁷ is followed in the urine and stool, U_{ca} = urinary stable Ca in milligrams during Δt , fs = fraction of intravenously administered Ca⁴⁷ in stool during Δt , and fu = fraction of intravenously administered Ca⁴⁷ in urine during Δt .

TABLE	11
Metabolic balance of calcium,	phosphorus, and nitrogen

				alcium			Pho	enhorue			Ni	rogen	
Subject	4-Day periods	Intake	Urine	Feces	Balance	Intake	Urine	Feces	Balance	Intake	Urine	Feces	Balance
	n 0.		g	/dav				/dav			g	/dav	
LE	1	.212	.033	.264	085	.774	.539	.331	096	11.09	9.26	1.21	+0.62
	2	.212	.032	.357	177	.774	.446	.443	115	11.09	8.87	1.54	+0.68
	3	.212	.025	.382	195	.//4	.433	.483	142	11.09	9.03	1.73	± 0.03
	5	.212	.015	.322	125	.774	.433	.426	095	11.09	9.65	1.40	+0.00
	Average	.212	.025	.335	148	.774	.459	.422	107	11.09	9.28	1.46	+0.34
ОТ	1	.205	.120	.337	252	.766	.522	.214	+.030	9.78	10.61	1.48	-2.31
	2	.205	.110	.290	195	.766	.667	.202	103	9.78	9.55	1.20	-0.97
	3	.205	.093	.372	200	.700	.030	.251	121	9.78	9.92	1.40	-1.00
	5	.205	.093	.354	240 238	.766	.559	.232	014 023	9.78	9.32	1.33	-0.99
	Average	.205	.105	.337	237	. 766	.588	.224	046	9.78	9.81	1.35	-1.38
NS [1]	1	.212	.319	.340	447	. 868	.759	.273	164	11.67	10.44	1.56	-0.33
	2	.212	.258	.456	052	. 868	.699	.368	199	11.67	9.22	1.63	+0.82
	3	.212	.245	.454	487	.868	.805	.300	237	11.67	9.24	1.71	+0.72
	4	.212	.200	.330	384	.808	.152	.238	122	11.07	0.02	1.10	+1.07
	Average	.212	.272	.395	455	.868	.754	.295	181	11.67	9.38	1.52	+0.77
NS [2]	1	.214	.091	.548	425	.862	.745	.476	359	11.52	12.29	2.28	-3.05
	2	.214	.078	.205	129	.862	.842	.232	212	11.52	12.19	1.05	1.72
	3 4	.214	.076	.735	384	.862	.790	.319	247	11.52	12.06	2.95	-2.65
	Average	.214	.080	.522	388	.862	.784	.407	329	11.52	12.16	2.10	-2.74
RF	1	.212	.272	.220	280	.873	1.025	.202	354	14.43	13.88	0.77	+0.28
	2	.212	.283	.387	458	.873	1.096	.351	574	14.43	15.02	1.15	-1.74
	3	.212	.265	.433	486	.873	.922	.396	445	14.43	12.83	1.68	-0.08
	4 5	.212	250	.202	311 471	.873	.740	.239	340	14.43	11.81	1.20	+0.88
	۰ ۸	212	266	217	401	972	041	272	264	14 43	13.02	1 21	+0.10
	Average	.212	.200	.347	401	.015	.941	.525	304	14.45	13.02	1.51	-0.10
AS	1	.511 .	.161	.528	178	.958	.590	.216	+.152	12.27	6.56	1.24	+4.47
	23	.511 .	170	.044 538	204 - 206	.958	.407	.209	+.281 018	12.27	7.31	1.00	+3.94 +3.54
	4	.511 .	172	.620	281	.958	.690	.405	137	12.27	6.26	1.56	+4.44
	5	.511 .	184	599	272	.958	.718	.383	-1.43	12.27	7.55	1.94	+2.77
	Average	.511 .	165	.586	240	.958	.617	.314	+.027	12.27	6.88	1.56	+3.83
нк	1	.530 .	061 .	.507 ·	038	1.148	.807	.390	049	13.09	12.54	1.09	-0.54
	2	.530 .	074 . 069	515 ·	059	1.148	.715	.400	+.033	13.09	11.70	1.32	+0.07
	3 4	.530 .	008 . 077	576 -	114	1.148	.750	.432	034 - 067	13.09	11.21	1.35	+0.02 +0.61
	5	.530	080	621	171	1.148	.801	.438	091	13.09	11.46	1.50	+0.13
	ō	.530	081	584 -	135	1.148	.759	.417	028	13.09	11.22	1.30	+0.58
	7	.530 .	071 .	527 -	068	1.148	.744	.367	+.037	13.09	11.20	1.25	+0.64
	8	.530 .0	078 .	452	.000	1.148	.749	.338	+.001	13.09	11.10	1.10	+0.//
	Average	.530 .0	074 .	538 -	082	1.148	.766	.400	018	13.09	11.53	1.28	+0.28

Subject	Intake	Absorbed	Unabsorbed	Endogenous fecal	Total fecal
LE	mg/day 210	mg/day	mg/day	mg/day >125†	mg/day 335
ОТ	205	25 iv	180 iv	155 iv	335
NS [1]	210	150 iv	60 iv	335 iv‡	395
NS [2]	215	5 p.o. -15 iv	210 p.o. 230 iv	310 p.o. 290 iv	520
FR	210	85 iv	125 iv	220 iv	345
AS	510	185 p.o. 165 iv	325 p.o. 345 iv	260 p.o. 240 iv	585
НК	530	105 p.o. 120 iv	425 p.o. 410 iv	115 p.o. 120 iv	540

TABLE III Estimation of calcium absorption and endogenous fecal calcium after oral, or intravenous Ca⁴⁷, or both*

* Values indicated by "iv" were determined from intravenous Ca⁴⁷ data, and those by "p.o.," from oral Ca⁴⁷ data. † Estimated from difference between total fecal calcium and intake. ‡ Estimated from 4-day stool collection.

After intravenous Ca47, radioactivity appeared in the urine within minutes, whereas radioactivity was not detected in the stool for 12 to 48 hours. To count cumulative activity in urine and stool for an identical interval (Δt) , the stool was monitored for an additional period, corresponding to this lag. For example, if no stool radioactivity was detectable for 24 hours, the urine activity would be monitored from days 1 to 7, while stool activity would be determined for days 2 to 8.

Calcium kinetics. The conceptual model employed to determine the miscible calcium pool (E) and "bone-formation rate" ("BFR") was that of Heaney and Whedon (15). The miscible calcium pool was determined by extrapolating the exponential portion of the serum specific activity curve to zero time and dividing the administered dose by the specific activity at zero time. An example of the exponential phase used in these studies is shown in Figure 1. "Bone-formation rates" were calculated by the formula proposed by Heaney and Whedon (15): BFR = $EK \ (1 - fu \infty - fs \infty)$, where E = miscible calcium pool, K = fractional rate of loss of isotope by all routes from pool E, $fu \infty$ = fraction of intravenuosly administered Ca⁴⁷ excreted in urine, and $fs \infty$ = fraction of intravenously administered Ca⁴⁷ excreted in stool. (Quotation marks are used because the evidence is not convincing that boneformation rate alone is being measured).

RESULTS

Balance studies. As shown in Table II, all untreated patients were in positive nitrogen-balance equilibrium, except OT. Studies I and II of NS will be discussed below under a separate heading.

		Cumulative Ca ⁴⁷ excretion								
Subject	 E*	K†	Urine	Days counted	Stool	Days counted	"Bone- formation rate"			
	mg/kg		% in- jected dose		% in- jected dose		mg/kg/day			
LE	90	.084	1.7	3 t	5.2	2	5.7			
ОТ	75	.164	9.5	7	13.8	7 .	10.6			
NS [1]	70	.209	20.0	6	9.2§	4	12.1			
NS [2]	103	.235	4.6	6	16.9	6	23.2			
RF	53	.165	22.7	7	19.1	7	7.1			
AS	98	.186	6.7	6	9.7	6	16.8			
нк	73	.169	5.6	6	9.6	6	11.4			
Normal										
values (15)	60-110						8-11			

TABLE IV 1 111

* Miscible calcium pool.

See legend of Figure 1 for the derivation of K. † Disappearance constant.

Unable to follow beyond 3 days, since patient had low urinary calcium and only 15 µc Ca⁴⁷ injected.

§ First 2 days' stool not counted.

All patients were in negative phosphorus balance or equilibrium. Calcium balance was distinctly negative in all patients, while they were ingesting 200 mg or 500 mg calcium per day (Table II). As can be seen from Tables I and II, the magnitude of the negative calcium balance, ranging from 90 to 455 mg per day, could be correlated with the severity of the skeletal involvement as judged by X-ray bone surveys. There was little fluctuation in the calcium excretion during the balance studies, as noted in Table II. Serum calcium and body weights were stable during the balance studies.

Absorbed dietary calcium. Calcium absorption, with oral Ca⁴⁷, was determined in NS, AS, and HK. In HK, the absorption study was repeated after 7 days with excellent agreement (16 and 22%). Estimates of calcium absorption for these patients, as well as for OT, NS, and RF were also obtained indirectly from the interrelationships given above after intravenous Ca⁴⁷. As can be seen from Table III, calcium absorption varied from 12 to 70%. All values in Table III have been rounded off to the nearest 5 mg.

Endogenous fecal calcium. In all patients except RF, the endogenous fecal calcium exceeded the urinary calcium excretion (Tables II and III). Endogenous fecal calcium was determined in patients NS, AS, and HK by both the intravenousand oral-tracer methods as described above. As Table III shows, the results obtained by the oral and intravenous methods are in excellent agreement. There appeared to be a distinct correlation between endogenous fecal calcium and total urinary calcium excretion (correlation coefficient = 0.862), but sample size is admittedly small.

Miscible calcium pool and Ca^{47} disappearance from serum. Figure 1 shows a representative disappearance curve after intravenous administration of 30 μ c Ca⁴⁷. In all patients except LE, the rate of disappearance of intravenous calcium label was found to be more rapid than in a group of normal control volunteers and patients with senile osteoporosis (15, 16). Despite the increased values for K, the estimates of the miscible calcium pool E were normal, except for patient RF, in whom it was reduced (Table IV). The abnormally rapid disappearance of intravenously administered labels in those patients with normal bone-formation rates was explained by the excessive excretion of isotope in urine and stool. All values for the "bone-formation rates" were essentially within normal limits, except for LE and AS, in whom values were reduced and elevated, respectively.

Patient NS. This patient strikingly demonstrated the importance of determining the total fecal calcium and its fractions. The data from NS, presented in detail in Figure 2, were of particular interest in that the studies revealed marked differences in the gastrointestinal and renal handling of calcium before and during 5-fluorouracil therapy. During the pretreatment study, the patient was in marked negative calcium balance. Absorption of dietary calcium while he was on a 210-mg calcium diet was approximately 70% (Table II). The endogenous fecal calcium was 335 mg per day, and the urinary calcium excretion, 270 mg per day. He then received a total of 33 g of 5-fluorouracil over 76 days, beginning approximately 60 days before the second study. When restudied after 80 days, calcium absorption was virtually zero (Table II), when measured with either oral or intravenous Ca⁴⁷. The endogenous fecal calcium was 290 mg per day, and the urinary calcium was markedly lower (80 mg per day) than during the pretreatment study. Without tracer Ca⁴⁷ studies, the profound effect of 5-fluorouracil on calcium absorption would not have been apparent. If urinary calcium alone were followed, as suggested by Meyers (17), a beneficial effect on bone mineral metabolism would have been assumed. An explanation for the increased "boneformation rate" in the second study is not apparent. The marked negative calcium balances during both studies, however, indicate bone resorption in excess of bone formation. The increased fecal nitrogen, as well as the decreased calcium absorption during 5-fluorouracil therapy. is consistent with this drug's cytotoxic effect on the mucosa of the small intestine.

DISCUSSION

Contrary to findings in normal subjects (18). the endogenous fecal calcium was greater than the urinary calcium in five of the six patients with multiple myeloma studied. This observation is especially significant since considerable controversy still exists regarding the importance of the gastrointestinal tract in endogenous calcium excretion.



FIG. 2. METABOLIC-BALANCE GRAPHS AND CA⁴⁷ SERUM DISAPPEARANCE STUDIES BEFORE AND DURING 5-FLUOROURACIL THERAPY. In the balance graphs, intake is plotted downward from the zero line. Fecal (stippled area) and urinary values (cross-hatched area) are plotted upward. E and K are determined as in Figure 1.

It has only been with the availability of Ca⁴⁵ and Ca⁴⁷ that endogenous fecal calcium could be approximated in a patient. Brine and Johnston (19) plotted fecal calcium against dietary calcium from 51 balance studies in the literature, and extrapolated the intake to zero. In this way, the endogenous fecal calcium was estimated to be 75 mg per day. Subsequently, endogenous fecal calcium has been studied in various diseases with radio-active calcium isotopes (20–23). Although endogenous fecal calcium has never been measured in multiple myeloma, Anderson and colleagues (5) reported a total digestive-juice calcium of 465 mg per day, with very wide daily fluctuations, in a single patient with this disease.

Initially in this study, the endogenous fecal calcium was calculated by the method of Comar. Monroe, Visek, and Hansard (24), relating total fecal isotopic activity to serum specific activity. This method assumes that the specific activity of the stool calcium follows that of the blood, but 24 hours later. Because preliminary observations with this technique yielded unsatisfactory results, the method described above was used. Aubert and Milhaud (25) and Bronner (26) have recently suggested a very similar method to determine endogenous fecal calcium. From oral Ca47tracer studies, a second, indirect value for endogenous fecal calcium, as well as a value for absorbed dietary calcium, was obtained. In patients NS, AS, and HK, the results for endogenous fecal calcium and absorbed dietary calcium, by the oraland intravenous-tracer methods, were in excellent agreement (Table III).

As Bronner recently pointed out (26), the factors determining endogenous fecal calcium are largely unknown. In our study, there appears to be no correlation with serum calcium, miscible calcium-pool size, or the dietary calcium levels used. There appeared to be a distinct correlation between endogenous fecal calcium and total urinary calcium (correlation coefficient = 0.862), but the population sample was admittedly too small to make this statistically significant, and more data are needed.

There have been several studies of calcium metabolism in malignant disease in which fecal calcium excretion has not been reported (27–29). Meyers (17) has stated that "decreases in serum and urinary calcium are not the result of increases in fecal calcium." Our results with patient NS contradict this observation. In a recent metabolicbalance and Sr⁸⁵-tracer study in a patient with multiple myeloma, Skoog and co-workers (7) claimed that Sr⁸⁵-excretion studies "emphasize the now known fact that endogenous calcium excretion is largely renal." Our studies as well as those quoted above (20–23) indicate that the gastrointestinal tract is a very significant route for endogenous calcium excretion. The multiple variables (30) influencing the preferential absorption of calcium over strontium preclude a simple extrapolation for calcium absorption, gut secretion, and urinary excretion from the strontium data alone.

Low-calcium diets were used for two reasons: to note small fluctuations in calcium balance that would be more apparent on the low intake than on a high-calcium diet, and to obviate the need for a change in calcium if one of the subjects studied became hypercalcemic. It has been known for many years (31) that normal controls on lowcalcium diets (less than 300 mg daily) persistently show a negative calcium balance of approximately 100 mg per day. Very similar results have been shown more recently (20, 32). In all of our patients, the negative calcium balance exceeded the value expected with the low-calcium intakes alone. These results are consistent with previously reported calcium-balance studies in myeloma patients on various calcium intakes (1, 2, 3, 5).

Calcium kinetics in various disorders have been studied with strontium and calcium isotopes. Assuming a single-compartment system, all but one (RF) of the values reported here for the miscible calcium pool were within normal limits (60 to 110 mg per kg). Normal miscible calcium-pool sizes have been reported by Heaney and Whedon (15) in subjects with a variety of disease processes including idiopathic osteoporosis and rheumatoid arthritis with osteoporosis, and by Bauer, Carlsson, and Lindquist (16) in subjects with leukemia and with nonpituitary brain tumors. The "bone-formation rates" in our patients varied from 5.7 to 11.8 mg per kg per day, with most values within the normal limits given by Heaney and Whedon (8 to 11 mg per kg per day). The calcium kinetics in our study are difficult to compare quantitatively with many other reported studies, since the experimental models and methods of calculation vary. At present, there is no consensus among investigators in the field regarding a satisfactory mathematical model with which the rates of bone formation and destruction can be accurately measured.

SUMMARY

The present report describes the results of combined metabolic-balance and Ca47-tracer studies in six normocalcemic, ambulatory patients with multiple myeloma. All patients were found to be in significantly negative calcium balance, but no consistent deviations in phosphorus or nitrogen balance were observed. The isotopic studies indicated that endogenous fecal calcium was a very significant route of calcium loss in these patients, exceeding urinary calcium in five of six patients. The results with combined oral and intravenous Ca47-tracer studies strongly suggest that accurate estimates of calcium absorption and endogenous fecal calcium excretion can be obtained with these techniques. The importance of determining the total fecal calcium, as well as of distinguishing unabsorbed dietary calcium and endogenous fecal calcium, is illustrated by the results in one patient before and during 5-fluorouracil therapy.

ACKNOWLEDGMENT

The authors are pleased to acknowledge the invaluable assistance of the personnel of the Metabolism Unit of the National Cancer Institute including Miss Elaine Gaddis, Mrs. Eileen Jones, Mrs. Lillian Fisher, and their respective staffs. The assistance of Mr. William Briner of the radiopharmacy is also gratefully acknowledged.

REFERENCES

- 1. Osserman, E. F. Plasma-cell myeloma. II. Clinical aspects. New Engl. J. Med. 1959, 261, 1952.
- Snapper, I. Multiple myeloma. Clin. Orthop. 1957, 9, 107.
- Blatherwick, N. R. Calcium and Bence-Jones protein excretion in multiple myeloma. Amer. J. med. Sci. 1916, 151, 432.
- Adams, W. S., E. D. Mason, and S. H. Bassett. Metabolic balance investigation of three cases of multiple myeloma during ACTH administration; exchanges of calcium, phosphorus, nitrogen and electrolytes. J. clin. Invest. 1954, 33, 103.
- Anderson, J., E. W. Emery, J. M. McAllister, and S. B. Osborn. The metabolism of a therapeutic dose of Ca⁴⁵ in a case of multiple myeloma. Clin. Sci. 1956, 15, 567.

- Spencer, H., M. Li, J. Samachson, and D. Laszlo. Metabolism of strontium-85 and calcium-45 in man. Metabolism 1960, 9, 916.
- Skoog, W., W. S. Adams, and N. S. MacDonald. Metabolic balance Sr⁸⁵ study of a patient with multiple myeloma treated with corticosteroids and androgens. Metabolism 1962, 11, 421.
- 8. Gutman, A. B., R. L. Tyson, and E. B. Gutman. Serum calcium, inorganic phosphorus and phosphatase activity: in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic diseases of the bone. Arch. int. Med. 1939, 57, 378.
- 9. Pierce, C. P., and E. L. Haenisch. Quantitative Analysis. New York, Wiley, 1950, p. 140.
- Taussky, H. H., and E. Shorr. A microcolorimetric method for the determination of inorganic phosphorus. J. biol. Chem. 1953, 202, 675.
- 11. Reiner, M. Standard Methods of Clinical Chemistry. New York, Academic Press, 1953, p. 84.
- Kochakian, J. D., and R. P. Fox. Microdetermination of calcium by titration of the oxalate with ammonium hexanitratocerate. Industr. Eng. Chem. 1944, 16, 762.
- MacIntyre, I. The flame spectro-photometric determination of calcium in biological fluids and isotopic analysis of the errors in the Kramer-Tisdall procedure. Biochem. J. 1957, 67, 164.
- Radiological Health Handbook. U. S. Dept. Health Educ. Welf. PB121784R, 1960, p. 238.
- Heaney, R. P., and G. D. Whedon. Radiocalcium studies of bone formation rate in human metabolic bone disease. J. clin. Endocr. 1958, 18, 1246.
- Bauer, G. C. H., A. Carlsson, and B. Lindquist. Bone salt metabolism in humans studied by means of radiocalcium. Acta med. scand. 1957, 158, 143.
- Meyers, W. P. L. Hypercalcemia in neoplastic disease. Arch. Surg. 1960, 80, 308.
- Bronner, F., R. S. Harris, C. J. Maletskos, and C. E. Benda. Studies in calcium metabolism. The fate of intravenously injected radiocalcium in human beings. J. clin. Invest. 1956, 35, 78.
- Brine, C. L., and F. A. Johnston. Endogenous calcium in the feces of adult man and the amount of calcium absorbed from food. Amer. J. clin. Nutr. 1955, 3, 418.
- Blau, M., H. Spencer, J. Swernov, and D. Laszlo. Utilization and intestinal excretion of calcium in man. Science 1954, 120, 1029.
- Spencer, H., D. Laszlo, and M. Brothers. Strontium⁸⁵ and calcium⁴⁵ metabolism in man. J. clin. Invest. 1957, 36, 680.
- 22. Bronner, F., C. E. Benda, R. S. Harris, and J. Kreplick. Calcium metabolism in a case of gar-goylism, studied with the aid of radiocalcium. J. clin. Invest. 1958, 37, 139.
- Nordin, B. E. C. Investigation of bone metabolism with calcium-47—a preliminary report. Proc. roy. Soc. B 1959, 52, 351.

- 24. Comar, C. L., R. A. Monroe, W. J. Visek, and S. L. Hansard. Comparison of two isotope methods for determination of endogenous fecal calcium. J. Nutrition 1953, 50, 459.
- Aubert, J-P., and G. Milhaud. Méthode de mesure des principales voies du métabolisme calcique chez l'homme. Biochim biophys. Acta (Amst.) 1960, 39, 122.
- Bronner, F. Experimental studies of calcium absorption in man. Nutr. et Deita (Basel) 1962, 3, 22.
- Meyers, W. P. L. Hypercalcemia in neoplastic disease. Cancer 1956, 9, 1135.
- Meyers, W. P. L. Calcium studies in malignant tumors. II. Application of simplified measurements to clinical problems. Cancer 1959, 12, 494.

- Kabakow, B., and H. Spencer. Effects of mytatrienediol in multiple myeloma, metastatic bone disease, and osteoporosis. Arch. intern. Med. 1960, 105, 905.
- Mraz, F. R. Intestinal absorption of Sr⁸⁵ and Ca⁴⁵ in Hanford Biology Research Annual Report for 1961, HW72500, 15.
- Bauer, W., F. Albright, and J. C. Aub. Studies of calcium and phosphorus metabolism. II. The calcium excretion of normal individuals on a low calcium diet, also data on a case of pregnancy. J. clin. Invest. 1929, 7, 75.
- 32. Berlin, N. I., D. M. Watkin, and N. R. Gevirtz. Measurement of changes in gross body composition during controlled weight reduction in obesity by metabolic balance and body density-body water techniques. Metabolism 1962, 11, 302.